Program - Society of Toxicology
Program - Society of Toxicology
Program - Society of Toxicology
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Society</strong> <strong>of</strong> <strong>Toxicology</strong> 2011<br />
<strong>Program</strong> Description (Continued)<br />
Abstract #<br />
#406 Poster Board Number.....................................827<br />
E7 VIRAL ONCOPROTEIN NEGATIVELY<br />
INFLUENCES THE TRANSCRIPTIONAL<br />
ACTIVITY OF THE L1MD<br />
RETROTRANSPOSON PROMOTER UNDER<br />
CONDITIONS OF CELLULAR STRESS. <br />
D. E. Montoya-Durango 1,2 and K. S. Ramos 1,2 .<br />
1<br />
Biochemistry and Molecular Biology, University <strong>of</strong><br />
Louisville, Louisville, KY and 2 Center for Genetics<br />
and Molecular Medicine, University <strong>of</strong> Louisville,<br />
Louisville, KY.<br />
#407 Poster Board Number.....................................828<br />
NEOPLASTIC LUNG CELL<br />
PROLIFERATION, STIMULATED BY<br />
ALVEOLAR MACROPHAGE-DERIVED<br />
IGF-1, CAN BE ABROGATED BY THE<br />
COMBINED INHIBITION OF MEK AND<br />
PI3K. J. M. Fritz, L. D. Dwyer-Nield and A. M.<br />
Malkinson. Department <strong>of</strong> Pharmaceutical Sciences,<br />
University <strong>of</strong> Colorado Denver, Aurora, CO.<br />
#408 Poster Board Number.....................................829<br />
MASS SPECTROMETRY TECHNIQUES TO<br />
STUDY PROTEIN-LIGAND INTERACTIONS<br />
AND MOLECULAR TOXICOLOGY<br />
PATHWAYS. K. E. Yamada 1,2 , C. M. Ryan 3 , J.<br />
P. Whitelegge 3 and C. D. Eckhert 1,2 . 1 Molecular<br />
<strong>Toxicology</strong> IDP, University <strong>of</strong> California Los<br />
Angeles, Los Angeles, CA, 2 Environmental Health<br />
Sciences, University <strong>of</strong> California Los Angeles, Los<br />
Angeles, CA and 3 The Pasarow Mass Spectrometry<br />
Laboratory, The NPI-Semel Institute, David Geffen<br />
School <strong>of</strong> Medicine, University <strong>of</strong> California Los<br />
Angeles, Los Angeles, CA.<br />
#409 Poster Board Number.....................................830<br />
DICLOFENAC INHIBITS TNF-INDUCED<br />
NF-B NUCLEAR SHUTTLING CAUSING<br />
SYNERGISTIC HEPATOCYTE APOPTOSIS<br />
VIA CASPASE-8. L. Fredriksson, B. Herpers, Z.<br />
Di and B. van de Water. <strong>Toxicology</strong>, LACDR, Leiden<br />
University, Leiden, Netherlands.<br />
#410 Poster Board Number.....................................831<br />
NRF2B: A NOVEL NRF2 PARALOG IN<br />
ZEBRAFISH. A. R. Timme-Laragy 1 , S. I.<br />
Karchner 1 , D. G. Franks 1 , M. J. Jenny 2 and M.<br />
E. Hahn 1 . 1 Biology, Woods Hole Oceanographic<br />
Institution, Woods Hole, MA and 2 University <strong>of</strong><br />
Alabama, Tuscaloosa, AL.<br />
#411 Poster Board Number.....................................832<br />
CRITICAL CYSTEINE RESIDUES OF<br />
KEAP1 IN SUPPRESSION OF NRF2 BASAL<br />
ACTIVITY AND ARSENIC-SENSING BY<br />
REGULATING THE UBIQUITINATION-<br />
PROTEASOMAL DEGRADATION OF NRF2<br />
PROTEIN. X. He 1 and Q. Ma 1,2 . 1 Receptor Biology<br />
Lab. /TMBB/HELD, NIOSH, Morgantown, WV and<br />
2<br />
Biochemistry, West Virginia University, School <strong>of</strong><br />
Medicine, Morgantown, WV.<br />
Abstract #<br />
#412 Poster Board Number.....................................833<br />
THE KEAP1-NRF2 SYSTEM REGULATES<br />
METALLOTHIONEIN EXPRESSION AND<br />
PROTECTS VASCULAR ENDOTHELIAL<br />
CELLS FROM CADMIUM CYTOTOXICITY. <br />
Y. Shinkai 1 , Y. Kumagai 1 , T. Kimura 2 , C. Yamamoto 3 ,<br />
M. Yamamoto 4 , H. Jinno 5 , T. Tanaka-Kagawa 5 and T.<br />
Kaji 6 . 1 Graduate School <strong>of</strong> Comprehensive Human<br />
Sciences, University <strong>of</strong> Tsukuba, Tsukuba, Japan,<br />
2<br />
Faculty <strong>of</strong> Pharmaceutical Sciences, Setsunan<br />
University, Osaka, Japan, 3 Faculty <strong>of</strong> Pharmaceutical<br />
Sciences, Hokuriku University, Kanazawa, Japan,<br />
4<br />
Graduate School <strong>of</strong> Medicine, Tohoku University,<br />
Sendai, Japan, 5 Division <strong>of</strong> Environmental<br />
Chemistry, National Institute <strong>of</strong> Health Sciences,<br />
Tokyo, Japan and 6 Faculty <strong>of</strong> Pharmaceutical<br />
Sciences, Tokyo University <strong>of</strong> Science, Noda, Japan.<br />
Sponsor: A. Naganuma.<br />
#413 Poster Board Number.....................................834<br />
MECHANISTIC INVOLVEMENT OF THE<br />
NRF2/KEAP1 ANTI-OXIDANT RESPONSE<br />
IN THE REGULATION OF HUMAN ABCC3. <br />
M. D. Merrell 1 , M. J. Canet 1 , F. Zhao 1 , T. Wu 1 , J.<br />
M. Maher 2 and N. J. Cherrington 1 . 1 Pharmacology<br />
and <strong>Toxicology</strong>, University <strong>of</strong> Arizona, Tucson, AZ<br />
and 2 Department <strong>of</strong> Medical Biochemistry, Tohoku<br />
University, Sendai, Japan.<br />
#414 Poster Board Number.....................................835<br />
ATTENUATION OF THE NRF2 SIGNALING<br />
PATHWAY IN HEPATOCYTES LACKING<br />
SIRTUIN 1 (SIRT1). W. Wei 1 , J. Xu 1 , S. Kulkarni 1 ,<br />
X. Li 2 and A. Slitt 1 . 1 BPS, University <strong>of</strong> Rhode<br />
Island, Kingston, RI and 2 National Institute <strong>of</strong><br />
Environmental Health Sciences, Research Triangle<br />
Park, NC.<br />
#415 Poster Board Number.....................................836<br />
RESPONSE OF NRF2-MODULATED GENES<br />
TO CIGARETTE SMOKE. B. Kosmider, E.<br />
Messier, H. Chu and R. J. Mason. National Jewish<br />
Health, Denver, CO.<br />
#416 Poster Board Number.....................................837<br />
INDIRUBIN-3’-(2, 3 DIHYDROXYPROPYL)-<br />
OXIMETHER (E804) IS A POTENT<br />
AHR-AGONIST AND MODULATOR OF<br />
INFLAMMATION PROFILES IN LPS-<br />
TREATED RAW264.7 MACROPHAGES. A.<br />
S. Babcock and C. D. Rice. Biological Sciences,<br />
Clemson University, Clemson, SC.<br />
Monday Morning, March 7<br />
10:30 AM to 11:30 AM<br />
Room 156<br />
Exhibitor Hosted Session: First in Human Monoclonal<br />
Antibody Development Strategies for the Treatment <strong>of</strong><br />
Cancer Patients<br />
Presented by: Huntingdon Life Sciences<br />
Monoclonal antibodies have demonstrated to provide huge healthcare<br />
benefits in treatment <strong>of</strong> cancer. Designing and performing the optimal IND<br />
enabling nonclinical safety package is very important. Some non-standard<br />
approaches are discussed which highlight the need for focus upon the pathophysiology<br />
<strong>of</strong> disease, the biology <strong>of</strong> the drug target and the risks that need<br />
to be considered with drug intervention.<br />
MONday<br />
Poster Sessions<br />
Regional Interest Session<br />
Roundtable Sessions<br />
Symposium Sessions<br />
Thematic Sessions<br />
Workshop Sessions<br />
149